Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: Result of a single-center, prospective randomized phase III trial

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1348-1353

  Zhang, R X ^a,b   Wu, X J ^a,b   Wan, D S ^a,b   Lu, Z H ^a,b   Kong, L H ^a,b   Pan, Z Z ^a,b   Chen, G ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Capecitabine; Celecoxib; Chemotherapy; Colorectal cancer; Hand foot syndrome; Management

Indexed keywords

CAPECITABINE; CELECOXIB; DIHYDROPYRIMIDINE DEHYDROGENASE; OXALIPLATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEPATOBILIARY DISEASE; HUMAN; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

EID: 84860442682     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr400     Document Type: Article

References (22)

1. Heidelberger C, Chaudhuri NK, Danneberg P et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-666.
2. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
3. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225-234.
4. Zuehlke R. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974; 148: 90-92.
5. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24: 457-461.
6. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12: 131-141.
7. Edward LIN, Jeffrey S, Morris et al. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 2002; 16: 31-37.
8. Lin EH, Curley SA, Crane CC et al. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol 2006; 29: 232-239.
9. Law CC, Fu YT, Chau KK et al. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with stage III colon cancer. DisColon Rectum 2006; 50(12): 2180-2187.
10. Abushullaih S, Saad ED, Munsell M et al. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a singleinstitution experience. Cancer Invest 2002; 20: 3-10.
11. Heo YS, Chang HM, Kim TW et al. Hand-foot syndrome in patients treated with capecitabinecontaining combination chemotherapy. J Clin Pharmacol 2004; 44: 1166-1172.
12. Haller DG, Cassidy J, Clarke SJ et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26: 2118-2123.
13. Kang YK, Lee SS, Yoon DH et al. Pyridoxine is not effective to prevent Hand-foot syndrome associated with capecitabine therapy: result of a randomized, doubleblind, placebo-controlled study. J Clin Oncol 2010; 28(24): 3824-3829.
14. Marse H, Van Cutsem E, Grothey A et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nursing 2004; 8: S16-S30.
15. Fabian CJ, Molina R, Slavik M et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57-63.
16. Gordon KB, Tajuddin A, Guitart J et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995; 75: 2169-2173.
17. Portal I, Cardenal F, Garcia-del-Muro X. Etoposide-related acral erythema. Cancer Chemother Pharmacol 1994; 34: 181.
18. Vukelja SJ, Baker WJ, Burris HA et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with Taxotere. J Natl Cancer Inst 1993; 85: 1432-1433.
19. Mortimer JE, Lauman MK, Tan B et al. Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract 2003; 9: 161-166.
20. Vail DM, Chun R, Thamm DH et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998; 4: 1567-1571.
21. Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537-3541.
22. Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355(9): 885-895.